Tumor - T-DXd and SRS for Brain Metastases: Efficacy and Toxicity

In this episode, we delve into the latest research on treating brain metastases in HER2-positive or -low breast cancer. We discuss a study published in Breast (Edinburgh, Scotland) in 2026, utilizing full-text access, which evaluated the combined impact of trastuzumab deruxtecan (T-DXd) and brain stereotactic radiosurgery (SRS). The research focused on assessing intracranial control and the risk of radionecrosis in patients with these specific types of brain metastases. Key findings shed light on how this therapeutic combination influences patient outcomes and potential side effects, offering crucial insights for clinical decision-making. This content is for informational purposes and does not constitute medical advice.